We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
A paper appearing in EMBC¹ reports a major advance in the study of sleep disorders. Oxford BioSignals, a spin-out company from Oxford University, has developed and validated BioSleep, a novel system based on neural network analysis, which not only elucidates the microstructure of sleep - fleeting changes which have never before been consistently demonstrated - but also reliably detects abnormal sleep patterns.
The 64th spin-out company from the University of Oxford, OxTox Ltd, will produce drug-testing kits for the police to use on drivers that are as reliable and easy to use as breathalysers for alcohol.
Zyentia Ltd, Oxford University's latest spin-out company from the Chemistry Department, the third within the last half year, is based on technology that has the potential to solve major problems in protein therapies.
A new company called TΔS (TDeltaS Ltd) has been spun-out of the University of Oxford based on findings made during research into human metabolism by Professor Kieran Clarke in the Department of Physiology, Anatomy and Genetics.
Oxford spin-outs have been busy raising finance. A total of nearly £50 million has been secured so far this year by some of the 50 companies spun-out by Oxford University Innovation from the University of Oxford, including those mentioned below.
Oxford University has signed a private equity deal, initially worth £12m, to help the funding of its new Institute of Biomedical Engineering (IBME) www.ibme.ox.ac.uk. The deal, struck with London’s City-based Technikos, also includes the provision of commercial and financial advice and assistance in return for shares in future spin-outs from IBME.
VASTox, a leading chemical genomics company, has announced that it has successfully raised £10.45 million in a placing of New Ordinary Shares to institutional investors.